Know Cancer

forgot password

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer Through Gene Expression Profiling.

Phase 2
18 Years
Not Enrolling
Advanced Non-Small Cell Lung Cancer

Thank you

Trial Information

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer Through Gene Expression Profiling.

Prior to the start of treatment, subjects will have a complete history and physical
examination and blood tests to evaluate their overall health. The doctor will also obtain a
tissue sample (biopsy) of the tumor taken from the subject's body to evaluate the genes that
are expressed within the tumor. Doctors from the University of Michigan will do an analysis
on the tissue to understand the genetic nature of each subject's tumor. If the subject's
initial surgery or biopsy was done at the University of Michigan, we may already have an
adequate sample of their cancer that could be used for this research. In that case, we
would be asking for their permission to use this sample for this study. However, if
subjects agree to participate in this research study and an adequate sample is not
available, they will need to undergo another biopsy procedure for us to obtain a sample of
your cancer.

A biopsy of a subject's tumor can be obtained from various sites of their body using a
number of different methods. We will select a location that will be the easiest and safest
place to biopsy, and that will provide an adequate sample of tumor tissue. Biopsy sites will
generally be superficial (for example, lymph nodes, skin nodules, chest wall tumors). The
usual method of biopsy will be the placement of a large needle into the tumor to obtain a
"core" of tissue. In some situations, we may ask to have a superficial tumor removed in
whole or part by a minor surgical procedure. If neither of these methods can be done safely,
we may place a thin needle into the tumor and aspirate (suck out) some tumor cells for
study. All procedures will be done with local anesthesia (that is, injection of medication
directly into the biopsy site to numb the area prior to biopsy) and appropriate care to
avoid excessive bleeding or subsequent infection. The doctors will explain the specific
biopsy location and technique that fits each subject's situation to them in detail prior to
the procedure. They can decide not to go through with the biopsy and withdraw from this
research trial at any time.

Subjects will then be given carboplatin and paclitaxel intravenously (through a vein) over 2
hours. This will be repeated every three weeks for a total of six to eighteen weeks. Three
weeks is considered a "cycle" and each subject will receive 1 to 6 cycles depending on how
their tumor responds and how the treatment is tolerated. Treatment will be stopped if the
tumor gets worse or if a subject develops unacceptable side-effects.

Physical examinations, blood tests, and x-rays and/or scans will be done routinely during
the therapy so the doctor can check the subject's body and your tumor response to treatment.
Blood samples, consisting of 2-3 teaspoonfuls (10-15 cc) each, will be obtained twice every
three weeks during the study to evaluate the effect of the treatment on their blood counts,
blood electrolytes, liver and kidney function.

Inclusion Criteria:

histologic or cytologic evidence of stage IIIB (with malignant pleural
effusion) or stage IV NSCLC; no prior chemotherapy; measurable disease; disease that is
amenable to biopsy; age 18 years; Zubrod performance status 0-2; adequate bone marrow,
hepatic and renal function; signed informed consent.

Exclusion Criteria: prior chemotherapy or radiation therapy to target lesions; pregnant or
lactating women; symptomatic or uncontrolled CNS metastases.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The ultimate goal of this study is to identify a tumor molecular profile using gene expression microarray data that is associated with responsiveness to carboplatin and paclitaxel.

Principal Investigator

Greg Kalemkerian, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Michigan Cancer Center


United States: Institutional Review Board

Study ID:

UMCC 2004.058



Start Date:

December 2004

Completion Date:

August 2006

Related Keywords:

  • Advanced Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752